This page shows the latest cHL news and features for those working in and with pharma, biotech and healthcare.
Since then, the immunotherapy has added an array of indications to its arsenal, including approvals for the treatment of head and neck squamous cell carcinoma, classical Hodgkin lymphoma (cHL), cervical cancer,
Tyvyt has also been approved in China for the treatment of relapsed or refractory classical Hodgkin’s lymphoma (cHL).
CHL is, in comparison to Keytruda’s other indications, not quite as important. ... That includes evaluating Keytruda in combination with chemotherapy in children and young adults in first-line cHL and in the post-Adcetris treatment setting.
cHL) in December.
The single-arm trial enrolled 70 cHL patients who had failed autologous stem cell transplantation (ASCT) – a primary treatment for the cancer – or were ineligible for the procedure.
Earlier this year Keytruda was approved for classical Hodgkin lymphoma (cHL) - its first non-solid tumour indication - and expanding into blood cancers is a key target for Merck.
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
CDA). The company is filing first for patients with relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) – a niche indication not yet taken in China by Keytruda and Opdivo, which
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...